Home/Pipeline/Anti-infectives / AMR Program

Anti-infectives / AMR Program

Drug-resistant infections

Pre-clinicalActive

Key Facts

Indication
Drug-resistant infections
Phase
Pre-clinical
Status
Active
Company

About AMPLY Discovery

AMPLY Discovery is an AI-driven drug discovery company founded in 2019, headquartered in Cambridge, UK. It has developed the AMPLYfolio AI platform, which mines digitized natural biological data to discover novel peptides, proteins, and RNAi therapeutics, subsequently producing and testing them via a bioprinting and validation pipeline. The company is pre-clinical and pre-revenue, having secured over $3 million in investment and grant funding from entities like Innovate UK. Its approach aims to democratize and accelerate the discovery of new drugs for complex diseases, starting with oncology and anti-infectives.

View full company profile